IDIA Stock Overview
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland.
Price History & Performance
|Historical stock prices|
|Current Share Price||CHF14.54|
|52 Week High||CHF26.58|
|52 Week Low||CHF12.64|
|1 Month Change||-6.31%|
|3 Month Change||-19.40%|
|1 Year Change||-45.01%|
|3 Year Change||-36.84%|
|5 Year Change||-28.73%|
|Change since IPO||6.52%|
Recent News & Updates
|IDIA||CH Biotechs||CH Market|
Return vs Industry: IDIA underperformed the Swiss Biotechs industry which returned -19.4% over the past year.
Return vs Market: IDIA underperformed the Swiss Market which returned -12.4% over the past year.
|IDIA Average Weekly Movement||7.2%|
|Biotechs Industry Average Movement||7.8%|
|Market Average Movement||4.6%|
|10% most volatile stocks in CH Market||7.6%|
|10% least volatile stocks in CH Market||2.4%|
Stable Share Price: IDIA is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: IDIA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy.
Idorsia Fundamentals Summary
|IDIA fundamental statistics|
Is IDIA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IDIA income statement (TTM)|
|Cost of Revenue||CHF411.64m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Jul 26, 2022
|Earnings per share (EPS)||-4.11|
|Net Profit Margin||-2,161.29%|
How did IDIA perform over the long term?See historical performance and comparison
Is IDIA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IDIA?
Other financial metrics that can be useful for relative valuation.
|What is IDIA's n/a Ratio?|
Price to Book Ratio vs Peers
How does IDIA's PB Ratio compare to its peers?
|IDIA PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
WBIO Wockhardt Bio
MOLN Molecular Partners
SANN Santhera Pharmaceuticals Holding
SFZN Siegfried Holding
Price-To-Book vs Peers: IDIA is good value based on its Price-To-Book Ratio (-21.3x) compared to the peer average (11x).
Price to Earnings Ratio vs Industry
How does IDIA's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Book vs Industry: IDIA is good value based on its Price-To-Book Ratio (-21.3x) compared to the Swiss Biotechs industry average (0.7x)
Price to Book Ratio vs Fair Ratio
What is IDIA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||-21.3x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate IDIA's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of IDIA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IDIA (CHF14.54) is trading above our estimate of fair value (CHF10.78)
Significantly Below Fair Value: IDIA is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IDIA's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Idorsia forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDIA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IDIA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IDIA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IDIA's revenue (51.4% per year) is forecast to grow faster than the Swiss market (4.2% per year).
High Growth Revenue: IDIA's revenue (51.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IDIA is forecast to be unprofitable in 3 years.
Discover growth companies
How has Idorsia performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDIA is currently unprofitable.
Growing Profit Margin: IDIA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IDIA is unprofitable, and losses have increased over the past 5 years at a rate of 25.8% per year.
Accelerating Growth: Unable to compare IDIA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IDIA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.4%).
Return on Equity
High ROE: IDIA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
How is Idorsia's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IDIA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: IDIA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: IDIA has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: IDIA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IDIA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IDIA has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 27.2% each year.
Discover healthy companies
What is Idorsia current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IDIA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IDIA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IDIA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IDIA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IDIA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jean-Paul Clozel (66 yo)
Mr. Jean-Paul Clozel, M.D., co- founded Actelion Ltd (alternate name Actelion AG ) in 1997 and has been its Chief Executive Officer since 1999. He is Executive Director at Idorsia Ltd. Mr. Clozel serves as...
Experienced Management: IDIA's management team is seasoned and experienced (5.2 years average tenure).
Experienced Board: IDIA's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6%.
Idorsia Ltd's employee growth, exchange listings and data sources
- Name: Idorsia Ltd
- Ticker: IDIA
- Exchange: SWX
- Founded: 2017
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CHF2.575b
- Shares outstanding: 177.08m
- Website: https://www.idorsia.com
Number of Employees
- Idorsia Ltd
- Hegenheimermattweg 91
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.